Physician profile
Dmitriy Ratsenberg
NPI 1912950858
$13,657.10
in general payments reported to CMS, 2019-2025
51 companies · $1,178 in 2025
The $1,178 reported for 2025 was more than what 87% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,102 · 2020: $1,866 · 2021: $2,836 · 2022: $2,110 · 2023: $1,745 · 2024: $1,820 · 2025: $1,178.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,744.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,743.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,315.80 | 2019-2025 | |
| Amgen INC. | $1,208.91 | 2019-2025 | Otezla, Repatha, Evenity |
| Novo Nordisk INC | $938.61 | 2019-2025 | Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals Lp | $926.86 | 2019-2025 | Farxiga, Breztri |
| Amarin Pharma, INC. | $863.70 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $661.45 | 2019-2025 | Xifaxan |
| Sumitomo Pharma America, INC. | $604.42 | 2023-2025 | Gemtesa |
| Pfizer INC. | $511.93 | 2019-2025 | |
| Lilly USA, LLC | $468.68 | 2019-2024 | Jardiance, Mounjaro, Emgality |
| Sanofi-Aventis U.S. LLC | $463.53 | 2019-2024 | |
| Glaxosmithkline, LLC. | $425.79 | 2022-2024 | Shingrix, Arexvy, Trelegy Ellipta |
| Aimmune Therapeutics, INC. | $411.20 | 2024-2025 | Zenpep |
| Boehringer Ingelheim Pharmaceuticals, INC. | $389.36 | 2019-2025 | Jardiance |
| Ironwood Pharmaceuticals, INC | $388.60 | 2019-2024 | Linzess |
| Merck Sharp & Dohme LLC | $353.83 | 2019-2022 |
Show all 51 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dmitriy Ratsenberg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.